Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Pharming Group N.V.NASDAQ: PHAR

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows in line with its trailing trend

Q1 FY2026 research & development of $25.56M rose 20.9% year over year, behind the +22.1% change in trailing-twelve-month research & development. Sequentially, it fell 20.3% from the prior quarter. Over 3 fiscal years it compounded at +23.1% a year.

Context

  • Research & development amounted to 26.0% of revenue in FY2025, down 2.0 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +20.9% toward the trailing-twelve-month pace of +22.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$25.56M-20.3% QoQ
Last fiscal yearDec 2025
$98.08M+13.9% YoY
LTMMar 2026
$104.71M+22.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.9%——
1 year+13.9%——
3-year CAGR+23.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
98.08M USD
Year-over-year change
+13.9%
4-year CAGR
+5.3%

Research & Development vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +22.1% is the 3rd highest of 9, against a peer median of +9.8%.
  • Research & development amounts to 28.3% of revenue for PHAR, versus a peer median of 329.9%.
PHAR Competitors
Research & Development for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$181.1B USD+19955.1%+12.4%17.6%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$923.16M USD+4.7%+3.2%96.2%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$361.17M USD-21.5%-2.5%546.5%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$197.76M USD+15.5%-13.1%21.0%
STOKStoke Therapeutics, Inc.LTM Mar 2026$144.07M USD+45.7%+21.0%449.1%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$137.53M USD-14.3%-5.0%—
PHVSPharvaris N.V.LTM Sep 2026€132.22M EUR+7.0%+29.5%—
PHARPharming Group N.V.LTM Mar 2026$104.71M USD+22.1%+23.1%28.3%
SLNSilence Therapeutics plcLTM Mar 2026$61.84M USD—+24.0%6710.8%
PRQRProQR Therapeutics N.V.LTM Mar 2026€44.34M EUR+12.6%-7.1%329.9%
Peer median (excluding PHAR) —+9.8%+3.2%329.9%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue225.46M205.62M245.32M307.75M377.18M
Cost of Revenue23.97M17.56M25.21M36.66M45.63M
Gross Profit201.49M188.06M220.1M271.09M331.56M
Gross Margin89.4%91.5%89.7%88.1%87.9%
Research & Development79.78M52.53M68.91M86.1M98.08M
Selling, General & Admin54.56M68.85M87.5M102.74M117.44M
Operating Expenses186.12M169.83M225.49M280.02M309.75M
Depreciation & Amortization22.23M13.19M15.93M16.64M10.76M
EBITDA55.3M33.53M9.88M16.89M31.7M
EBITDA Margin24.5%16.3%4.0%5.5%8.4%
Operating Income15.37M18.23M(5.39M)(8.93M)20.88M
Operating Margin6.8%8.9%-2.2%-2.9%5.5%
Interest Income59.99K85K3.53M5.92M2.56M
Interest Expense7M5.36M5.96M9.05M21.31M
Other Income / Expenses10.79M(3.25M)(6.63M)133.58K(8.03M)
Income Before Tax26.16M14.99M(12.01M)(8.79M)12.88M
Pre-Tax Margin11.6%7.3%-4.9%-2.9%3.4%
Income Tax Expense8.03M1.31M(1.46M)3.47M10.34M
Net Income18.13M13.67M(10.55M)(12.26M)2.86M
Net Margin8.0%6.7%-4.3%-4.0%0.8%
EPS (Basic)0.230.17(0.14)(0.18)0.04
EPS (Diluted)0.210.16(0.14)(0.18)0.04
Weighted Avg Shares87.64M82.54M65.7M68.92M71.32M
Weighted Avg Shares (Diluted)87.64M84.28M65.7M68.92M71.32M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.